The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over competitors’ more frequent regimens.
I-Mab said the measure ensures cash reserves to keep the company operational until 2027. Image credit: Brian A Jackson / Shutterstock Cancer immunotherapy biotech I-Mab, has paused the development of ...
There have been several impactful clinical trial read outs in 2024. Image credit: Shutterstock / Rajitha Tennakoon From gene therapies to psychedelics and cancer vaccines to HIV pre-exposure ...
Chime Biologics and Mabgeek have completed the Process Performance Qualification (PPQ) for the humanised anti-IL-4Rα monoclonal antibody, MG-K10, advancing it into Phase III clinical trials for a ...